Clinical trials: Transitional Cell Carcinoma of Urinary Bladder
Non-muscle Invasive Bladder Cancer
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
- Trial name
- NCT02138734
- Testing
- BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation)
- Where
- 108 sites in United States, India and 1 more
- Volunteers
- 369 people
- Sponsor
- ImmunityBio, Inc.
Bladder Cancer
Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- GEMCIRAV (NCT00556621)
- Testing
- cisplatin, gemcitabine hydrochloride, biopsy
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Bladder Cancer
Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
Phase I: To determine the safety, toxicity and efficacy profiles of intravesically administered Abraxane at the Maximum Tolerated Dose.
- Trial name
- NCT00583349
- Testing
- Abraxane
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Columbia University
Bladder (Urothelial, Transitional Cell) Cancer, TURBT
INTRAOPERATIVE BLADDER INJURY ASSESSMENT IN TURBT USING BICEP
Transurethral resection of bladder tumor (TURBT) is the cornerstone procedure in the diagnosis and treatment of bladder cancer but is associated with a spectrum of intraoperative bladder injuries ranging from minor mucosal tears…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, TURBT, Bladder Injury
- Trial name
- BICEP in TURBT (NCT07396038)
- Testing
- No intervention is assigned as part of this observational study. All procedures are performed as part of routine clinical care.
- Volunteers
- 1,000 people
- Sponsor
- Necmettin Erbakan University
Recurrent Bladder Cancer, Stage I Bladder Cancer
Gene Therapy in Treating Patients With Advanced Bladder Cancer
Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer
- Conditions
- Recurrent Bladder Cancer, Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
- Trial name
- NCT00003167
- Testing
- Ad5CMV-p53 gene
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Hematuria, Acute Cystitis With Hematuria
Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?
This prospective multicenter observational study evaluates whether women ≥50 years with isolated acute hemorrhagic cystitis (AHC) and macroscopic hematuria require full malignancy workup.
- Conditions
- Hematuria, Acute Cystitis With Hematuria, Bladder Cancer, Urothelial Carcinoma
- Trial name
- BLUSH (NCT07037589)
- Testing
- investigation setting (cystoscopy + CTU + cytology), Cystoscopy - CTU - cytology (if needed)
- Where
- Sweden
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Bladder Cancer
Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006118
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 12 sites in France, Monaco
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Bladder (Urothelial, Transitional Cell) Cancer, MRI
Bp-MRI Based Multi-planar VI-RADS
This study is a prospective, single-center, observational clinical trial, enrolling 100 patients with malignant bladder tumors admitted to the Department of Urology at the People's Hospital of Jiangsu Province for treatment with…
- Trial name
- NCT06607250
- Testing
- MRI
- Where
- China
- Volunteers
- 95 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bladder Cancer
Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
The goal of this clinical research study is to learn about the tolerability of nivolumab in patients who have bladder cancer, were previously treated with BCG immunotherapy, and who have a cystectomy (removal of all or part of…
- Trial name
- NCT03106610
- Testing
- Nivolumab, Questionnaires
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Urothelial Carcinoma, Bladder Cancer
Safety Analysis and Oncological Outcomes in HoLERT vs TURBT
Bladder urothelial cancer is the second most common urologic tumor and represents a worldwide public health problem. Most cases are diagnosed as non-muscle invasive tumors, and can be treated with transurethral resection of…
- Trial name
- NCT05833997
- Testing
- Monopolar Transurethral resection of bladder tumor, Holmium Laser resection of bladder tumor (HoLEBT)
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Bladder Cancer
Markers of Response to Intravesical Bladder Cancer Therapy
The goal of this laboratory research study is to see if researchers can predict whose cancer will stay in remission and whose will return in patients receiving treatment for bladder cancer.
- Trial name
- NCT01007058
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced or Metastatic Urothelial Carcinoma
Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma
Phase II, multicenter, non-randomized, single-arm, open-label trial of atezolizumab in combination of split-doses of gemcitabine plus cisplatin in patients with locally advanced or metastatic urothelial carcinoma.
- Trial name
- AUREA (NCT04602078)
- Testing
- Atezolizumab 1200 mg/m2, Gemcitabine 1000 mg/m2, Cisplatin 70 mg/m2
- Where
- 12 sites in Spain
- Volunteers
- 82 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Bladder Cancer
Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer and may have fewer side effects and improve recovery.
- Trial name
- NCT00003725
- Testing
- valrubicin, conventional surgery
- Where
- 53 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Anthra Pharmaceuticals
Hematuria, Urothelial Carcinoma
Urine DNA Methylation Detection for Hematuria Evaluation
Background: Hematuria, a common symptom of urinary system diseases, can result from various causes including infection, stones, trauma, and tumors.
- Conditions
- Hematuria, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
- Trial name
- NCT06427993
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Changhai Hospital
Bladder Cancer
Surgery and BCG in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00002990
- Testing
- BCG vaccine
- Where
- 40 sites in Austria, Belgium and 9 more
- Volunteers
- 1,288 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the standard of care and be enrolled in the study for 12 months post-op.
- Conditions
- Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy
- Trial name
- NCT07234968
- Testing
- Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Thomas Jefferson University